Valuation: Inhalation Sciences Sweden AB

Market Cap 41.47L 4L 4L 3L 3L 6L 3.97Cr 6L 16.07L 2.03Cr 15.51L 15.18L 6.52Cr P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 13.16L 1L 1L 1L 99.12T 2L 1.26Cr 2L 5L 64.44L 5L 5L 2.07Cr EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
99.4%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 16/09/2019
Chief Tech/Sci/R&D Officer - 01/01/2005
Corporate Officer/Principal - 02/06/2025
Director TitleAgeSince
Director/Board Member - 01/01/2005
Director/Board Member - 01/09/2022
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4L
+0.35%-2.99%+20.52%+31.06% 24TCr
+1.09%-4.65%-0.43%-0.76% 15TCr
-2.32%-3.27%-13.35%+36.07% 14TCr
-1.46%-3.01%-56.23%-17.35% 6.17TCr
-0.05%-1.32%+10.48%+22.34% 4.91TCr
+0.66%+0.19%-20.53%-20.70% 4.74TCr
+0.66%-2.90%+18.46%+52.17% 4.73TCr
-3.05%-2.62%-7.75%+36.49% 4.43TCr
-0.08%-1.92%+29.48%+60.45% 4.18TCr
Average -0.42%-2.50%-2.15%+22.20% 9.14TCr
Weighted average by Cap. -0.29%-3.27%+1.08%+21.95%

Financials

2024 2025
Net sales 1.1Cr 11.01L 10L 9L 8L 15.69L 11Cr 15.84L 42.81L 5.41Cr 41.33L 40.43L 17Cr 30.41L 3L 3L 3L 2L 4L 2.91Cr 4L 11.78L 1.49Cr 11.38L 11.13L 4.78Cr
Net income -51.47L -5L -5L -4L -4L -7L -4.93Cr -7L -19.94L -2.52Cr -19.26L -18.84L -8.09Cr -1.02Cr -10.12L -9L -8L -8L -14.43L -9.73Cr -14.57L -39.37L -4.98Cr -38.01L -37.19L -16Cr
Net Debt -40.03L -4L -4L -3L -3L -6L -3.83Cr -6L -15.51L -1.96Cr -14.98L -14.65L -6.29Cr -28.31L -3L -3L -2L -2L -4L -2.71Cr -4L -10.97L -1.39Cr -10.59L -10.36L -4.45Cr
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5

Net sales - Rate of surprise